Caladrius Biosciences SVP and President of PCT, Robert Preti, PhD, Named Chairman of the Alliance for Regenerative Medicine
June 27 2016 - 7:30AM
Caladrius Biosciences (Nasdaq:CLBS), a cell therapy company
combining an industry-leading development and manufacturing
services provider (PCT, LLC, a Caladrius company) with a select
therapeutic development pipeline announces that Robert A. Preti,
Ph.D., the Company’s Chief Technology Officer, Senior Vice
President, Manufacturing and Technical Operations, and President of
PCT, has been named Chairman of the Alliance for Regenerative
Medicine (ARM), the international advocacy organization
representing the gene and cell therapies and broader regenerative
medicine sector. Dr. Preti has served as Vice Chairman of ARM since
January 2015 and succeeds Edward Lanphier as Chairman.
Previous to his role as Vice Chairman, Dr. Preti was Executive
Committee member and co-chair of the Science and Technology
Committee at ARM. As Vice Chair, Dr. Preti has been responsible for
the support and promotion of ARM’s global strategy aimed at
increasing funding for research and the commercial development of
advanced gene- and cell-based therapies, as well as addressing
industry issues around regulatory science and reimbursement that
will support marketing approval and subsequent commercial
acceptance of safe and effective regenerative medicine
products.
“It has been a rewarding experience working with ARM both since
its founding and in an executive capacity in recent years, and I’m
excited to continue that relationship by serving as Chairman,” said
Dr. Preti. “ARM’s dedication to advancing regenerative medicine and
cell therapies and to bringing its stakeholders together is
unprecedented, and aligns with PCT’s own vision of contributing to
a world in which transformative cell-based therapeutics are
accessible to all patients in need.”
“With this transition, we welcome Bob’s expanded leadership role
at ARM as our new chairman,” said Morrie Ruffin, managing director,
ARM. “He brings deep knowledge of the organization, unparalleled
experience as a leader in the cell and gene therapy sectors and a
keen understanding of the clinical and commercial requirements for
success.”
Dr. Preti is co-founder of PCT and the visionary behind its
successful growth and development over much of the last two
decades. Dr. Preti founded PCT to meet a recognized need for
high quality manufacturing and development services in an emerging
industry. His leadership has been instrumental in creating PCT’s
client-focused model that helps bridge the gap between discovery
and patient care through efficient transfer of cell-based therapies
from laboratory to clinical practice to commercialization.
Before founding PCT, Dr. Preti held a number of positions within
the cellular therapy and blood banking fields. In addition, Dr.
Preti has served on the Stem Cell Banking Committee and Cord Blood
Subcommittee of the New York State Department of Health and on the
New Jersey State Department of Health’s Blood Bank Advisory
Committee, chairing the Hematopoietic Progenitor Cell Processing
Subcommittee. He has served in a leadership capacity for many
professional organizations, including Treasurer and founding member
of the International Society of Hematotherapy and Graft
Engineering, now called ISCT (International Society for Cellular
Therapy). He has published and presented extensively on a variety
of topics relating to cellular therapies. He recently completed a
five-year term as a director for AABB (formerly the American
Association of Blood Banks).
About the Alliance for Regenerative
Medicine
The Alliance for Regenerative Medicine is the preeminent global
advocate for regenerative and advanced therapies. ARM fosters
research, development, investment and commercialization of
transformational treatments and cures for patients worldwide.
By leveraging the expertise of its membership, ARM empowers
multiple stakeholders to promote legislative, regulatory and public
understanding of, and support for, this expanding field.
Based in Washington, DC, ARM promotes legislative, regulatory,
reimbursement, investment, technical and other initiatives to
accelerate the development of safe and effective regenerative
medicine technologies. ARM also works to increase public
understanding of the field and its potential to transform human
healthcare. Today ARM has more than 240 members and is the leading
global advocacy organization in this field.
About Caladrius Biosciences
Caladrius Biosciences, Inc., through its subsidiary, PCT, is a
leading development and manufacturing partner to the cell therapy
industry. PCT works with its clients to overcome the
fundamental challenges of cell therapy manufacturing by providing a
wide range of innovative services including product and process
development, GMP manufacturing, engineering and automation, cell
and tissue processing, logistics, storage and distribution, as well
as expert consulting and regulatory support. PCT and Hitachi
Chemical Co., Ltd. have entered into a strategic global
collaboration to accelerate the creation of a global commercial
cell therapy development and manufacturing enterprise with deep
engineering expertise. Around the core expertise of PCT,
Caladrius strategically develops select product candidates, which
currently includes an innovative therapy for type 1 diabetes based
on a proprietary platform technology for immunomodulation. For more
information, visit www.caladrius.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements reflect management’s current
expectations, as of the date of this press release, and involve
certain risks and uncertainties. All statements other than
statements of historical fact contained in this press release are
forward-looking statements. The Company’s actual results could
differ materially from those anticipated in these forward-looking
statements as a result of various factors. Factors that could cause
future results to materially differ from the recent results or
those projected in forward-looking statements include the “Risk
Factors” described in the Company’s Annual Report on Form 10-K
filed with the Securities and Exchange Commission (“SEC”) on March
15, 2016, and in the Company’s other periodic filings with the SEC.
The Company’s further development is highly dependent on, among
other things, future medical and research developments and market
acceptance, which are outside of its control.
CONTACTS:
Investors:
LHA
Anne Marie Fields
Senior Vice President
Phone: +1-212-838-3777
Email: afields@lhai.com
Media:
Caladrius Biosciences, Inc.
Eric Powers
Director, Communications and Marketing
Phone: +1-212-584-4173
Email: epowers@caladrius.com
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Sep 2023 to Sep 2024